

Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis

Ivanka Dimova¹, Beatrice Orsetti², Vincent Negre², Carole Rouge², Liza Ursule², Laurence Lasorsa², Rumen Dimitrov³, Nikolai Doganov³, Draga Toncheva¹, and Charles Theillet²

¹Department of Medical Genetics, Medical University, Sofia, Bulgaria; ²Identity and Plasticity of Tumors, INSERM/Université Montpellier I, CRLC Val D'Aurelle-Paul Lamarque, Montpellier, France; ³Clinics of Operative Gynecology, University Hospital of Obstetrics and Gynecology, Sofia, Bulgaria

ABSTRACT

Aims and background. The literature data show that the most frequently affected chromosomes in ovarian carcinogenesis are 1, 8 and 17. In the present study we aimed to define more precisely at a high resolution the genomic imbalances of these chromosomes in ovarian cancer and to determine genomic markers separating tumors of different histological types and stages.

Methods. Array comparative genomic hybridization (CGH) with a resolution of ≈0.8 Mb was applied in 28 primary ovarian tumors. We identified regions of highly frequent gains or losses (affecting more than 40% of ovarian cancers) and determined sites showing alterations of elevated amplitude (amplifications or homozygous deletions). Doing this we also identified at least two adjacent changed clones.

Results. We determined anomalies strongly associated with the disease such as deletions at 8p21-23, 17p12-13, 1p35-36 or amplifications at 1q23, 17q12, 17q23.2, 8q13.2, 8q24. We defined more precisely the gains in 17q12-q24, finding as strong candidates for ovarian tumorigenesis the genes *LASP1* (17q12), *TGF11* (17q21.32), *MUL* (17q23.2), *TBX2* (17q23.2), *AXIN2* (17q24.3) and *GRB2* (17q25.1). Of particular note was gain of 8q13.2, which occurred at a high frequency in ovarian cancer, especially in serous and late-stage tumors. We found that gains of 1q32-1q43, 8p11-p12, 8q11.23, 8q13.2, and 8q24.21-8q24.22 and losses of 1p36.21, 8p23.1-8p21.1 and 8q21.2 were associated with serous histology, whereas losses of 1q23 and 1q32-43 and gains of 17q11.2-12 and 17q25 were associated with mucinous histology. Gains of 1q23, 8q24, 17q23.2, 17q24.2 and losses of 1p35-36, 8p, 17p, and 17q were specific for late-stage ovarian cancers.

Conclusions. Our study has identified potential genomic markers of interest on chromosomes 1, 8 and 17 in ovarian cancer. Tumors showed a wide variety in the patterns of alteration, suggesting that alternative mechanisms of genomic instability may play a role in this tumor type.

Key words: ovarian cancer, array CGH, genomic instability, oncogenes.

Acknowledgments: This study was supported by the EUROGENDIS Training Site (contract No. QLGA-CT-2000-60005) and by an infrastructural project of the Ministry of Education and Science of Bulgaria (contract No. DRI-5). We express many thanks to our colleagues of the Laboratory of Experimental Oncology, Caen, France for the ovarian cancer samples provided for the study.

Correspondence to: Ivanka Dimova, MD, PhD, Department of Medical Genetics, Medical University, 2 Zdrave Str., 1431 Sofia, Bulgaria.
Tel/fax +359-2-952 0357;
e-mail idimova73@yahoo.com

Received October 16, 2008;
accepted January 12, 2009.